FDA gives breakthrough designation for psychedelic treatment
Mental Health Weekly March 22, 2024 DOI: 10.1002/mhw.33996 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Key points | The FDA granted Breakthrough Therapy Designation for a psychedelic-based adjunctive therapy for major depressive disorder. |
Abstract
A clinical‐stage biopharmaceutical company that officials said is committed to revolutionizing mental health care by developing new and innovative next‐generation psychedelic‐based treatment options, announced last week that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for an adjunctive psychedelic‐based therapy for the treatment of major depressive disorder (MDD), according to the press release news outlet, Businesswire.